Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 734-735, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sinicco, A.
Right arrow Articles by Di Perri, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinicco, A.
Right arrow Articles by Di Perri, G.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2000;46:734-735.)
© 2000 American Association for Clinical Chemistry, Inc.

Letters

Efavirenz Interference in Estradiol ELISA Assay

Alessandro Sinicco, Riccardo Raiteri, Antonella Rossati, Andrea Savarino and Giovanni Di Perria

Clinica delle Malattie Infettive, University of Turin, 10149 Turin, Italy
a Address correspondence to this author at: Clinica delle Malattie Infettive, Università di Torino, Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Torino, Italy. Fax 39-011-4393972; e-mail di_perri@dealer.it.


To the Editor:

The prognosis of HIV infection has dramatically changed following the introduction of highly active antiretroviral therapy (HAART), a multidrug regimen usually consisting of three to four antiretroviral drugs belonging to the categories of nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs) and of protease inhibitors (PIs). The somewhat remarkable therapeutic properties of these regimens are often associated to some degree of toxicity and side effects, also resulting from drug interactions. These occur both among antiretrovirals and between the latter and unrelated compounds (1), thus implying some restriction in the use of various drugs in several clinical circumstances.

The novel NNRTI efavirenz, a drug exerting an intrinsic antiretroviral activity of the same order of magnitude as PIs (2), was found to increase by 37% the area under the curve of coadministered ethinyl estradiol (3), an effect thought to result from interaction with . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
S. Rossi, T. Yaksh, H. Bentley, G. van den Brande, I. Grant, and R. Ellis
Characterization of interference with 6 commercial {delta}9-tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine.
Clin. Chem., May 1, 2006; 52(5): 896 - 897.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. E. Nelson, S. K. Grebe, D. J. O'Kane, and R. J. Singh
Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Measurement of Estradiol and Estrone in Human Plasma
Clin. Chem., February 1, 2004; 50(2): 373 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Z. Cao, T. A. Swift, C. A. West, T. G. Rosano, and R. Rej
Immunoassay of Estradiol: Unanticipated Suppression by Unconjugated Estriol
Clin. Chem., January 1, 2004; 50(1): 160 - 165.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.